Log in to save to my catalogue

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a...

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1682204958

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

About this item

Full title

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

Publisher

England: Elsevier Ltd

Journal title

The Lancet (British edition), 2015-05, Vol.385 (9980), p.1843-1852

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background The optimum duration of first-line treatment with chemotherapy in combination with bevacizumab in patients with metastatic colorectal cancer is unknown. The CAIRO3 study was designed to determine the efficacy of maintenance treatment with capecitabine plus bevacizumab versus observation. Methods In this open-label, phase 3, rando...

Alternative Titles

Full title

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1682204958

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1682204958

Other Identifiers

ISSN

0140-6736

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(14)62004-3

How to access this item